Leerink Partnrs Issues Negative Outlook for Certara Earnings

Certara, Inc. (NASDAQ:CERT) – Stock analysts at Leerink Partnrs decreased their FY2027 earnings per share estimates for Certara in a report released on Friday, April 4th. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings per share of $0.37 for the year, down from their previous forecast of $0.38. The consensus estimate for Certara’s current full-year earnings is $0.28 per share.

CERT has been the subject of a number of other reports. William Blair reiterated a “market perform” rating on shares of Certara in a research report on Thursday, February 27th. Stephens reiterated an “overweight” rating and set a $17.00 price target on shares of Certara in a report on Thursday, February 27th. TD Cowen initiated coverage on Certara in a report on Thursday, February 27th. They set a “buy” rating and a $16.00 price objective on the stock. Finally, Barclays upped their target price on Certara from $12.00 to $13.00 and gave the stock an “equal weight” rating in a report on Friday, February 28th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $15.83.

Certara Stock Down 1.9 %

Shares of NASDAQ CERT opened at $9.37 on Monday. The stock has a 50-day moving average price of $12.06 and a two-hundred day moving average price of $11.40. Certara has a 12 month low of $8.72 and a 12 month high of $19.18. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The company has a market cap of $1.51 billion, a price-to-earnings ratio of -46.85, a PEG ratio of 9.29 and a beta of 1.64.

Institutional Trading of Certara

Several institutional investors have recently modified their holdings of the business. Blue Trust Inc. lifted its holdings in Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after buying an additional 822 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Certara by 3.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 23,720 shares of the company’s stock worth $253,000 after acquiring an additional 823 shares during the period. Wells Fargo & Company MN boosted its holdings in Certara by 48.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock valued at $34,000 after acquiring an additional 1,047 shares during the last quarter. Bank of Montreal Can boosted its holdings in Certara by 9.1% in the fourth quarter. Bank of Montreal Can now owns 19,943 shares of the company’s stock valued at $212,000 after acquiring an additional 1,670 shares during the last quarter. Finally, Versant Capital Management Inc increased its position in Certara by 218.8% during the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company’s stock valued at $27,000 after purchasing an additional 1,866 shares during the period. Institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.